Aplastic anemia medical therapy: Difference between revisions
/* Specific Treatment of Aplastic Anaemia: General Comments {{cite journal| author=Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al.| title=Guidelines for the diagnosis and management of aplastic anaemia. | journal=Br J ... |
No edit summary |
||
| Line 20: | Line 20: | ||
}} | }} | ||
==Specific Treatment of Aplastic Anaemia: General Comments <ref name="pmid19673883">{{cite journal| author=Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al.| title=Guidelines for the diagnosis and management of aplastic anaemia. | journal=Br J Haematol | year= 2009 | volume= 147 | issue= 1 | pages= 43-70 | pmid=19673883 | doi=10.1111/j.1365-2141.2009.07842.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19673883 }} </ref> (DONOT EDIT)== | |||
{{cquote| | |||
===General Comments=== | |||
* Infection or uncontrolled [[bleeding]] should be treated first before giving [[immunosuppressive]] therapy. | |||
* This also applies to patients scheduled for [[bone marrow transplant]] (BMT), although it may sometimes be necessary to proceed straight to BMT in the presence of severe infection as a BMT may offer the best chance of early neutrophil recovery. | |||
* Haemopoietic growth factors, such as rHuEPO or G-CSF, should not be used on their own in newly diagnosed patients in an attempt to 'treat' the aplastic anaemia. | |||
* [[Prednisolone]] should not be used to treat patients with aplastic anaemia because it is ineffective and encourages bacterial and fungal infection. | |||
}} | |||
==Specific Treatment of Aplastic Anaemia: General Comments <ref name="pmid19673883">{{cite journal| author=Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al.| title=Guidelines for the diagnosis and management of aplastic anaemia. | journal=Br J Haematol | year= 2009 | volume= 147 | issue= 1 | pages= 43-70 | pmid=19673883 | doi=10.1111/j.1365-2141.2009.07842.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19673883 }} </ref> (DONOT EDIT)== | ==Specific Treatment of Aplastic Anaemia: General Comments <ref name="pmid19673883">{{cite journal| author=Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al.| title=Guidelines for the diagnosis and management of aplastic anaemia. | journal=Br J Haematol | year= 2009 | volume= 147 | issue= 1 | pages= 43-70 | pmid=19673883 | doi=10.1111/j.1365-2141.2009.07842.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19673883 }} </ref> (DONOT EDIT)== | ||
| Line 37: | Line 48: | ||
}} | }} | ||
==References== | ==References== | ||
Revision as of 15:08, 23 September 2012
|
Aplastic anemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Aplastic anemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Aplastic anemia medical therapy |
|
Risk calculators and risk factors for Aplastic anemia medical therapy |
Editor-In-Chief: Aric Hall, M.D., Beth Israel Deaconess Medical Center, Boston, MA [1]
Overview
Medical therapy of aplastic anemia often includes a short course of anti-thymocyte globulin (ATG or anti-lymphocyte globulin) and several months of treatment with cyclosporin to modulate the immune system. Mild chemotherapy with agents such as cyclophosphamide and vincristine may also be effective. Antibodies therapy, such as ATG, targets T-cells, which are believed to attack the bone marrow. Steroids are generally ineffective.
Medical Therapy
Supportive Care in treatment of aplastic anemia [1] (DONOT EDIT)
| “ |
Supportive Care
|
” |
Specific Treatment of Aplastic Anaemia: General Comments [1] (DONOT EDIT)
| “ |
General Comments
|
” |
Specific Treatment of Aplastic Anaemia: General Comments [1] (DONOT EDIT)
| “ |
General CommentsHuman Leucocyte Antigen (HLA)-identical Sibling Donor Transplantation Allogeneic BMT from an HLA-identical sibling donor is the initial treatment of choice for newly diagnosed patients if they have severe or very severe aplastic anaemia, are <40 years old, and have an HLA-compatible sibling donor. Patients with Fanconi anaemia and other types of inherited aplastic anaemia need special consideration and should not follow recommendations made in this guideline. There is no indication for using irradiation-based conditioning regimens for patients undergoing HLA-identical sibling BMT for aplastic anaemia. The recommended source of stem cells for transplantation in aplastic anaemia is bone marrow. Fertility is well preserved after high dose cyclophosphamide conditioning in BMT for aplastic anaemia, and patients should be given appropriate contraceptive advice to prevent unwanted pregnancy. Until longer term data is available in patients receiving fludarabine-based regimens, cryopreservation of sperm and oocytes should be planned.
|
” |
References
- ↑ 1.0 1.1 1.2 Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC; et al. (2009). "Guidelines for the diagnosis and management of aplastic anaemia". Br J Haematol. 147 (1): 43–70. doi:10.1111/j.1365-2141.2009.07842.x. PMID 19673883.